218 related articles for article (PubMed ID: 37207191)
1. CD4
Li X; Xu L; Lu L; Liu X; Yang Y; Wu Y; Han Y; Li X; Li Y; Song X; Cao W; Li T
Front Cell Infect Microbiol; 2023; 13():1178788. PubMed ID: 37207191
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis B surface antigen declines and clearance during long-term tenofovir therapy in patients coinfected with HBV and HIV.
Zoutendijk R; Zaaijer HL; de Vries-Sluijs TE; Reijnders JG; Mulder JW; Kroon FP; Richter C; van der Eijk AA; Sonneveld MJ; Hansen BE; de Man RA; van der Ende ME; Janssen HL
J Infect Dis; 2012 Sep; 206(6):974-80. PubMed ID: 22782950
[TBL] [Abstract][Full Text] [Related]
3. Higher risk of mortality in HIV-HBV co-infected patients from sub-Saharan Africa is observed at lower CD4
Kouamé GM; Gabillard D; Moh R; Badje A; Ntakpé JB; Emième A; Maylin S; Toni TD; Ménan H; Zoulim F; Danel C; Anglaret X; Eholié S; Lacombe K; Boyd A
Antivir Ther; 2021; 26(1-2):25-33. PubMed ID: 35485344
[TBL] [Abstract][Full Text] [Related]
4. The kinetics of the hepatitis B surface antigen level after the initiation of antiretroviral therapy for hepatitis B virus and human immunodeficiency virus coinfected patients.
Mitsumoto F; Murata M; Ura K; Takayama K; Hiramine S; Shimizu M; Toyoda K; Ogawa E; Furusyo N; Hayashi J
J Infect Chemother; 2015 Apr; 21(4):264-71. PubMed ID: 25596071
[TBL] [Abstract][Full Text] [Related]
5. HBV pgRNA profiles in Chinese HIV/HBV coinfected patients under pre- and posttreatment: a multicentre observational cohort study.
Xu L; Li X; Lu L; Liu X; Song X; Li Y; Han Y; Zhu T; Cao W; Li T
J Viral Hepat; 2022 Aug; 29(8):616-626. PubMed ID: 35582838
[TBL] [Abstract][Full Text] [Related]
6. HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes.
Hamers RL; Zaaijer HL; Wallis CL; Siwale M; Ive P; Botes ME; Sigaloff KC; Hoepelman AI; Stevens WS; Rinke de Wit TF;
J Acquir Immune Defic Syndr; 2013 Oct; 64(2):174-82. PubMed ID: 23892239
[TBL] [Abstract][Full Text] [Related]
7. Incidence and factors associated with hepatitis B surface antigen seroclearance in patients co-infected with HBV/HIV during antiretroviral therapy in Guangdong, China.
He Y; Lin W; Li H; Gu F; Zhong H; Lan Y; Li Y; Guo P; Hu F; Cai W; Tang X; Li L
Chin Med J (Engl); 2023 Nov; 136(22):2686-2693. PubMed ID: 37881959
[TBL] [Abstract][Full Text] [Related]
8. HBcAb seropositivity is correlated with poor HIV viremia control in an Italian cohort of HIV/HBV-coinfected patients on first-line therapy.
Malagnino V; Cerva C; Maffongelli G; Teti E; Foroghi Biland L; Cesta N; De Masi M; Stingone C; Armenia D; Svicher V; Salpini R; Andreoni M; Sarmati L
Sci Rep; 2019 Aug; 9(1):11942. PubMed ID: 31420570
[TBL] [Abstract][Full Text] [Related]
9. Viral determinants predicting hepatitis B surface antigen (HBsAg) seroclearance in HIV-/HBV-coinfected patients.
Strassl R; Reiberger T; Honsig C; Payer BA; Mandorfer M; Grabmeier-Pfistershammer K; Rieger A; Kundi M; Grundtner P; Peck-Radosavljevic M; Popow-Kraupp T
J Viral Hepat; 2014 Jul; 21(7):508-16. PubMed ID: 24112778
[TBL] [Abstract][Full Text] [Related]
10. Lamivudine Monotherapy-Based cART Is Efficacious for HBV Treatment in HIV/HBV Coinfection When Baseline HBV DNA <20,000 IU/mL.
Li Y; Xie J; Han Y; Wang H; Zhu T; Wang N; Lv W; Guo F; Qiu Z; Li Y; Du S; Song X; Thio CL; Li T
J Acquir Immune Defic Syndr; 2016 May; 72(1):39-45. PubMed ID: 26745828
[TBL] [Abstract][Full Text] [Related]
11. Improved immune status corresponds with long-term decline of quantitative serum hepatitis B surface antigen in HBV/HIV co-infected patients.
Arendt E; Jaroszewicz J; Rockstroh J; Meyer-Olson D; Zacher BJ; Mederacke I; Manns MP; Wedemeyer H; Cornberg M; Wursthorn K
Viral Immunol; 2012 Dec; 25(6):442-7. PubMed ID: 23131018
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B surface antigen concentrations in patients with HIV/HBV co-infection.
Jaroszewicz J; Reiberger T; Meyer-Olson D; Mauss S; Vogel M; Ingiliz P; Payer BA; Stoll M; Manns MP; Schmidt RE; Flisiak R; Wedemeyer H; Peck-Radosavljevic M; Rockstroh J; Cornberg M
PLoS One; 2012; 7(8):e43143. PubMed ID: 22905219
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis B surface antigen quantification as a predictor of seroclearance during treatment in HIV-hepatitis B virus coinfected patients from Sub-Saharan Africa.
Boyd A; Maylin S; Moh R; Mahjoub N; Gabillard D; Eholié SP; Danel C; Anglaret X; Zoulim F; Girard PM; Delaugerre C; Lacombefor K;
J Gastroenterol Hepatol; 2016 Mar; 31(3):634-44. PubMed ID: 26313291
[TBL] [Abstract][Full Text] [Related]
14. Long-term observation on hepatitis B surface antigen seroclearance in therapy experienced HIV/HBV co-infected Chinese.
Yang R; Gui X; Ke H; Xiong Y; Gao S
J Viral Hepat; 2020 Feb; 27(2):127-134. PubMed ID: 31571343
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis B surface antigen and hepatitis B RNA changes in HIV/hepatitis B virus co-infected participants receiving hepatitis B virus-active antiretroviral therapy.
Hawkins C; Kang M; Bhattacharya D; Cloherty G; Kuhns M; Matining R; Thio C; Samaneka W; Chinula L; Mulinda N; Badal-Faesen S; Sugandhavesa P; Lama J; Gaseitsiwe S; Holzmayer V; Anderson M; Murphy R; Peters M
AIDS; 2022 Jun; 36(7):975-984. PubMed ID: 35165216
[TBL] [Abstract][Full Text] [Related]
16. Virological Response to Tenofovir Disoproxil Fumarate in HIV-Positive Patients with Lamivudine-Resistant Hepatitis B Virus Coinfection in an Area Hyperendemic for Hepatitis B Virus Infection.
Huang YS; Chang SY; Sheng WH; Sun HY; Lee KY; Chuang YC; Su YC; Liu WC; Hung CC; Chang SC
PLoS One; 2016; 11(12):e0169228. PubMed ID: 28033344
[TBL] [Abstract][Full Text] [Related]
17. Impact of hepatitis B virus infection on human immunodeficiency virus response to antiretroviral therapy in Nigeria.
Idoko J; Meloni S; Muazu M; Nimzing L; Badung B; Hawkins C; Sankalé JL; Ekong E; Murphy R; Kanki P; Thio CL
Clin Infect Dis; 2009 Oct; 49(8):1268-73. PubMed ID: 19772386
[TBL] [Abstract][Full Text] [Related]
18. [Survival analysis on HIV/AIDS cases newly received antiretroviral therapy who coinfected with hepatitis B virus in Jiangsu Province, 2005-2020].
Qiu T; Ding P; Zhang Z; Zhai XJ
Zhonghua Liu Xing Bing Xue Za Zhi; 2024 Feb; 45(2):220-224. PubMed ID: 38413060
[No Abstract] [Full Text] [Related]
19. Prevalence and molecular characterization of hepatitis B virus infection in HIV-infected children in Senegal.
Toyé RM; Lô G; Diop-Ndiaye H; Cissé AM; Ndiaye AJS; Kébé-Fall K; Dramé A; Cohen D; Pujol FH; Mboup S; Boye CS; Chemin I; Laborde-Balen G; Taverne B; Touré-Kane C
Clin Res Hepatol Gastroenterol; 2021 Mar; 45(2):101502. PubMed ID: 32828748
[TBL] [Abstract][Full Text] [Related]
20. [A case of hepatitis B virus/human immunodeficiency virus coinfection in a patient who achived hepatitis B surface antigen seroclearance after interferon therapy followed by antiretroviral therapy without developing immune reconstitution inflammatory syndrome].
Mitsumoto F; Murata M; Ikezaki H; Ogawa E; Taniai H; Toyoda K; Otaguro S; Kainuma M; Okada K; Furusyo N; Hayashi J
Kansenshogaku Zasshi; 2012 Nov; 86(6):763-7. PubMed ID: 23367852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
